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Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human
drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared
to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.14750. Nuclear hormone receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-
coupled receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key
references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2019, and supersedes
data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and
Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classiﬁcation (NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug targets, where
appropriate.
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© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Overview: Nuclear receptors are specialised transcription fac-
tors with commonalities of sequence and structure, which bind
as homo- or heterodimers to speciﬁc consensus sequences of
DNA (response elements) in the promoter region of particular
target genes. They regulate (either promoting or repressing)
transcription of these target genes in response to a variety of en-
dogenous ligands. Endogenous agonists are hydrophobic enti-
ties which, when bound to the receptor promote conformational
changes in the receptor to allow recruitment (or dissociation) of
protein partners, generating a large multiprotein complex.
Two major subclasses of nuclear receptors with identiﬁed endoge-
nous agonists can be identiﬁed: steroid and non-steroid hormone
receptors. Steroid hormone receptors function typically as dimeric
entities and are thought to be resident outside the nucleus in the
unliganded state in a complex with chaperone proteins, which
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are liberated upon agonist binding. Migration to the nucleus
and interaction with other regulators of gene transcription, in-
cluding RNA polymerase, acetyltransferases and deacetylases, al-
lows gene transcription to be regulated. Non-steroid hormone
receptors typically exhibit a greater distribution in the nucleus in
the unliganded state and interact with other nuclear receptors to
form heterodimers, as well as with other regulators of gene tran-
scription, leading to changes in gene transcription upon agonist
binding.
Selectivity of gene regulation is brought about through
interaction of nuclear receptors with particular consen-
sus sequences of DNA, which are arranged typically as re-
peats or inverted palindromes to allow accumulation of
multiple transcription factors in the promoter regions of
genes.
Family structure
S230 1A. Thyroid hormone receptors
S231 1B. Retinoic acid receptors
S232 1C. Peroxisome proliferator-activated receptors
S233 1D. Rev-Erb receptors
S234 1F. Retinoic acid-related orphans
S234 1H. Liver X receptor-like receptors
S235 1I. Vitamin D receptor-like receptors
S236 2A. Hepatocyte nuclear factor-4 receptors
S237 2B. Retinoid X receptors
S238 2C. Testicular receptors
S238 2E. Tailless-like receptors
S239 2F. COUP-TF-like receptors
S239 3B. Estrogen-related receptors
S240 4A. Nerve growth factor IB-like receptors
S241 5A. Fushi tarazu F1-like receptors
S241 6A. Germ cell nuclear factor receptors
S242 0B. DAX-like receptors
S242 Steroid hormone receptors
S243 3A. Estrogen receptors
S244 3C. 3-Ketosteroid receptors
1A. Thyroid hormone receptors
Nuclear hormone receptors → 1A. Thyroid hormone receptors
Overview: Thyroid hormone receptors (TRs, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [39]) are nuclear hormone receptors of the NR1A
family, with diverse roles regulating macronutrient metabolism, cognition and cardiovascular homeostasis. TRs are activated by thyroxine (T4) and thyroid hormone (triiodothyronine). Once activated
by a ligand, the receptor acts as a transcription factor either as a monomer, homodimer or heterodimer with members of the retinoid X receptor family. NH-3 has been described as an antagonist at TRs
with modest selectivity for TRβ [105].
Nomenclature Thyroid hormone receptor-α Thyroid hormone receptor-β
Systematic nomenclature NR1A1 NR1A2
HGNC, UniProt THRA, P10827 THRB, P10828
Rank order of potency triiodothyronine > T4 triiodothyronine > T4
Agonists dextrothyroxine [17] dextrothyroxine [17]
Selective agonists – sobetirome [23, 125]
Comments: An interaction with integrin αVβ3 has been suggested to underlie plasma membrane localization of TRs and non-genomic signalling [6].One splice variant, TRα2, lacks a functional DNA-
binding domain and appears to act as a transcription suppressor.
Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available.
Searchable database: http://www.guidetopharmacology.org/index.jsp 1A. Thyroid hormone receptors S230
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Further reading on 1A. Thyroid hormone receptors
Elbers LP et al. (2016) Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.
Curr Atheroscler Rep 18: 14 [PMID:26886134]
Flamant F et al. (2006) International Union of Pharmacology. LIX. The pharmacology and classi-
ﬁcation of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol. Rev. 58:
705-11 [PMID:17132849]
Mendoza A et al. (2017) New insights into thyroid hormone action. Pharmacol. Ther. 173: 135-145
[PMID:28174093]
1B. Retinoic acid receptors
Nuclear hormone receptors → 1B. Retinoic acid receptors
Overview: Retinoic acid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [44]) are nuclear hormone receptors of the NR1B family
activated by the vitamin A-derived agonists tretinoin (ATRA) and alitretinoin, and the RAR-selective synthetic agonists TTNPB and adapalene. BMS493 is a family-selective antagonist [45].
Nomenclature Retinoic acid receptor-α Retinoic acid receptor-β Retinoic acid receptor-γ
Systematic nomenclature NR1B1 NR1B2 NR1B3
HGNC, UniProt RARA, P10276 RARB, P10826 RARG, P13631
Agonists tretinoin [22] tretinoin [22] tretinoin [22]
Sub/family-selective agonists tazarotene [22] tazarotene [22], adapalene [21] tazarotene [22], adapalene [21]
Selective agonists BMS753 [51], tamibarotene [143], Ro 40-6055 [30] AC261066 [84], AC55649 [83, 84] AHPN [21]
Selective antagonists Ro 41-5253 (pIC50 6.3–7.2) [1, 65] – MM 11253 [72]
Comments: Ro 41-5253 has been suggested to be a PPARγ agonist [124]. LE135 is an antagonist with selectivity for RARα and RARβ compared with RARγ [80].
Further reading on 1B. Retinoic acid receptors
Duong V et al. (2011) The molecular physiology of nuclear retinoic acid receptors. From health to
disease. Biochim. Biophys. Acta 1812: 1023-31 [PMID:20970498]
Germain P et al. (2006) International Union of Pharmacology. LX. Retinoic acid receptors. Pharma-
col. Rev. 58: 712-25 [PMID:17132850]
Larange A et al. (2016) Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the
Immune System. Annu. Rev. Immunol. 34: 369-94 [PMID:27168242]
Saeed A et al. (2017) The interrelationship between bile acid and vitamin A homeostasis. Biochim.
Biophys. Acta 1862: 496-512 [PMID:28111285]
Searchable database: http://www.guidetopharmacology.org/index.jsp 1B. Retinoic acid receptors S231
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1C. Peroxisome proliferator-activated receptors
Nuclear hormone receptors → 1C. Peroxisome proliferator-activated receptors
Overview: Peroxisome proliferator-activated receptors (PPARs,
nomenclature as agreed by the NC-IUPHAR Subcommit-
tee on Nuclear Hormone Receptors [96]) are nuclear hor-
mone receptors of the NR1C family, with diverse roles regulating
lipid homeostasis, cellular differentiation, proliferation and the
immune response. PPARs have many potential endogenous ag-
onists [11, 96], including 15-deoxy-12,14-PGJ2, prostacyclin
(PGI2), many fatty acids and their oxidation products,
lysophosphatidic acid (LPA) [93], 13-HODE, 15S-HETE, Paz-PC,
azelaoyl-PAF and leukotriene B4 (LTB4). Bezaﬁbrate acts as a
non-selective agonist for the PPAR family [152]. These recep-
tors also bind hypolipidaemic drugs (PPARα) and anti-diabetic
thiazolidinediones (PPARγ), as well as many non-steroidal anti-
inﬂammatory drugs, such as sulindac and indomethacin. Once
activated by a ligand, the receptor forms a heterodimer with
members of the retinoid X receptor family and can act as a tran-
scription factor. Although radioligand binding assays have been
described for all three receptors, the radioligands are not com-
mercially available. Commonly, receptor occupancy studies are
conducted using ﬂuorescent ligands and truncated forms of the
receptor limited to the ligand binding domain.
Nomenclature Peroxisome proliferator-activated receptor-α Peroxisome proliferator-activated receptor-β/δ Peroxisome proliferator-activated receptor-γ
Systematic nomenclature NR1C1 NR1C2 NR1C3
HGNC, UniProt PPARA, Q07869 PPARD, Q03181 PPARG, P37231
Selective agonists GW7647 [15, 16], CP-775146 [63], pirinixic acid [152],
gemﬁbrozil [28]
GW0742X [48, 137], GW501516 [107] GW1929 [15], bardoxolone (Partial agonist) [146],
rosiglitazone [55, 76, 158], troglitazone [55, 158],
pioglitazone [55, 122, 158], ciglitazone [55]
Selective antagonists GW6471 (pIC50 6.6) [155] GSK0660 (pIC50 6.5) [126] T0070907 (pKi 9) [73], GW9662 (Irreversible inhibition)
(pIC50 8.1) [74], CDDO-Me (pKi 6.9) [146]
Comments: As with the estrogen receptor antagonists, many agents show tissue-selective efﬁcacy (e.g. [10, 104, 119]). Agonists with mixed activity at PPARα and PPARγ have also been described (e.g [31,
50, 156]).
Further reading on 1C. Peroxisome proliferator-activated receptors
Cheang WS et al. (2015) The peroxisome proliferator-activated receptors in cardiovascular diseases:
experimental beneﬁts and clinical challenges. Br. J. Pharmacol. 172: 5512-22 [PMID:25438608]
Gross B et al. (2017) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol
13: 36-49 [PMID:27636730]
Hallenborg P et al. (2016) The elusive endogenous adipogenic PPARγ agonists: Lining up the sus-
pects. Prog. Lipid Res. 61: 149-62 [PMID:26703188]
Michalik L et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-
activated receptors. Pharmacol. Rev. 58: 726-41 [PMID:17132851]
Sauer S. (2015) Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma. Trends
Pharmacol. Sci. 36: 688-704 [PMID:26435213]
Searchable database: http://www.guidetopharmacology.org/index.jsp 1C. Peroxisome proliferator-activated receptors S232
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1D. Rev-Erb receptors
Nuclear hormone receptors → 1D. Rev-Erb receptors
Overview: Rev-erb receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an endogenous ligand,
but are thought to be activated by heme.
Nomenclature Rev-Erb-α Rev-Erb-β
Systematic nomenclature NR1D1 NR1D2
HGNC, UniProt NR1D1, P20393 NR1D2, Q14995
Endogenous agonists heme [116, 157] heme [92, 116, 157]
Selective agonists GSK4112 [49], GSK4112 [68] –
Selective antagonists SR8278 (pIC50 6.5) [68] –
Further reading on 1D. Rev-Erb receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Gonzalez-Sanchez E et al. (2015) Nuclear receptors in acute and chronic cholestasis. Dig Dis 33:
357-66 [PMID:26045270]
Gustafson CL et al. (2015) Emergingmodels for themolecular basis of mammalian circadian timing.
Biochemistry 54: 134-49 [PMID:25303119]
Sousa EH et al. (2017) Drug discovery targeting heme-based sensors and their coupled activities. J.
Inorg. Biochem. 167: 12-20 [PMID:27893989]
Searchable database: http://www.guidetopharmacology.org/index.jsp 1D. Rev-Erb receptors S233
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1F. Retinoic acid-related orphans
Nuclear hormone receptors → 1F. Retinoic acid-related orphans
Overview: Retinoic acid receptor-related orphan receptors (ROR, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be assigned a
deﬁnitive endogenous ligand, although RORα may be synthesized with a ‘captured’ agonist such as cholesterol [61, 62].
Nomenclature RAR-related orphan receptor-α RAR-related orphan receptor-β RAR-related orphan receptor-γ
Systematic nomenclature NR1F1 NR1F2 NR1F3
HGNC, UniProt RORA, P35398 RORB, Q92753 RORC, P51449
Endogenous agonists cholesterol [62, 109] – –
Selective agonists 7-hydroxycholesterol [12], cholesterol sulphate [12, 62] – –
Comments – – The immune system function of RORC proteins most likely resides with
expression of the RORγt isoform by immature CD4+/CD8+ cells in the thymus
[33, 136] and in lymphoid tissue inducer (LTi) cells [34].
Comments: Tretinoin shows selectivity for RORβ within the ROR family [131]. RORα has been suggested to be a nuclear receptor responding to melatonin [151].
Further reading on 1F. Retinoic acid-related orphans
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Cyr P et al. (2016) Recent progress on nuclear receptor RORγ modulators. Bioorg. Med. Chem. Lett.
26: 4387-4393 [PMID:27542308]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Guillemot-Legris O et al. (2016) Oxysterols in Metabolic Syndrome: From Bystander Molecules to
Bioactive Lipids. Trends Mol Med 22: 594-614 [PMID:27286741]
Mutemberezi V et al. (2016) Oxysterols: From cholesterol metabolites to key mediators. Prog. Lipid
Res. 64: 152-169 [PMID:27687912]
1H. Liver X receptor-like receptors
Nuclear hormone receptors → 1H. Liver X receptor-like receptors
Overview: Liver X and farnesoid X receptors (LXR and FXR, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [100]) are members of a steroid
analogue-activated nuclear receptor subfamily, which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXRs
appear to be activated by bile acids. In humans and primates, NR1H5P is a pseudogene. However, in other mammals, it encodes a functional nuclear hormone receptor that appears to be involved in
cholesterol biosynthesis [108].
Searchable database: http://www.guidetopharmacology.org/index.jsp 1H. Liver X receptor-like receptors S234
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Nomenclature Farnesoid X receptor Farnesoid X receptor-β Liver X receptor-α Liver X receptor-β
Systematic nomenclature NR1H4 NR1H5 NR1H3 NR1H2
HGNC, UniProt NR1H4, Q96RI1 NR1H5P, – NR1H3, Q13133 NR1H2, P55055
Potency order chenodeoxycholic acid > lithocholic acid,
deoxycholic acid [87, 110]
– 20S-hydroxycholesterol,
22R-hydroxycholesterol,
24(S)-hydroxycholesterol >
25-hydroxycholesterol,
27-hydroxycholesterol [75]
20S-hydroxycholesterol,
22R-hydroxycholesterol,
24(S)-hydroxycholesterol >
25-hydroxycholesterol,
27-hydroxycholesterol [75]
Endogenous agonists – lanosterol [108] – Mouse – –
Selective agonists GW4064 [89], obeticholic acid [111],
fexaramine [32]
– – –
Selective antagonists guggulsterone (pIC50 5.7–6) [154] – – –
Comments: T0901317 [117] and GW3965 [24] are synthetic agonists acting at both LXRα and LXRβ with less than 10-fold selectivity.
Further reading on 1H. Liver X receptor-like receptors
Courtney R et al. (2016) LXR Regulation of Brain Cholesterol: From Development to Disease. Trends
Endocrinol. Metab. 27: 404-414 [PMID:27113081]
El-Gendy BEM et al. (2018) Recent Advances in the Medicinal Chemistry of Liver X Receptors. J.
Med. Chem. 61: 10935-10956 [PMID:30004226]
Gadaleta RM et al. (2010) Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and
gastrointestinal disease. Biochim. Biophys. Acta 1801: 683-92 [PMID:20399894]
Merlen G et al. (2017) Bile acids and their receptors during liver regeneration: "Dangerous protec-
tors". Mol. Aspects Med. 56: 25-33 [PMID:28302491]
Moore DD et al. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors:
constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X
receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol.
Rev. 58: 742-59 [PMID:17132852]
Mouzat K et al. (2016) Liver X receptors: from cholesterol regulation to neuroprotection-a new bar-
rier against neurodegeneration in amyotrophic lateral sclerosis? Cell. Mol. Life Sci. 73: 3801-8
[PMID:27510420]
Schulman IG. (2017) Liver X receptors link lipid metabolism and inﬂammation. FEBS Lett. 591:
2978-2991 [PMID:28555747]
1I. Vitamin D receptor-like receptors
Nuclear hormone receptors → 1I. Vitamin D receptor-like receptors
Overview: Vitamin D (VDR), Pregnane X (PXR) and Constitutive Androstane (CAR) receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors
[100]) are members of the NR1I family of nuclear receptors, which form heterodimers with members of the retinoid X receptor family. PXR and CAR are activated by a range of exogenous compounds,
with no established endogenous physiological agonists, although high concentrations of bile acids and bile pigments activate PXR and CAR [100].
Searchable database: http://www.guidetopharmacology.org/index.jsp 1I. Vitamin D receptor-like receptors S235
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Nomenclature Vitamin D receptor Pregnane X receptor Constitutive androstane receptor
Systematic nomenclature NR1I1 NR1I2 NR1I3
HGNC, UniProt VDR, P11473 NR1I2, O75469 NR1I3, Q14994
Endogenous agonists 1,25-dihydroxyvitamin D3 [9, 37] 17β-estradiol [60] –
Selective agonists seocalcitol [25, 150], doxercalciferol hyperforin [101, 149], 5β-pregnane-3,20-dione [60],
lovastatin [77], rifampicin [13, 77]
TCPOBOP [141] – Mouse, CITCO [86]
Selective antagonists TEI-9647 (pIC50 8.2) [121] – Chicken, ZK159222 (pIC50
7.5) [40, 56]
– –
Comments – – Clotrimazole [102] and T0901317 [64] although acting at
other sites, function as antagonists of the constitutive
androstane receptor.
Further reading on 1I. Vitamin D receptor-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Long MD et al. (2015) Vitamin D receptor and RXR in the post-genomic era. J. Cell. Physiol. 230:
758-66 [PMID:25335912]
Moore DD et al. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors:
constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X
receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol.
Rev. 58: 742-59 [PMID:17132852]
2A. Hepatocyte nuclear factor-4 receptors
Nuclear hormone receptors → 2A. Hepatocyte nuclear factor-4 receptors
Overview: The nomenclature of hepatocyte nuclear factor-4 receptors is agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]. While linoleic acid has been identiﬁed as
the endogenous ligand for HNF4α its function remains ambiguous [160]. HNF4γ has yet to be paired with an endogenous ligand.
Nomenclature Hepatocyte nuclear factor-4-α Hepatocyte nuclear factor-4-γ
Systematic nomenclature NR2A1 NR2A2
HGNC, UniProt HNF4A, P41235 HNF4G, Q14541
Endogenous agonists linoleic acid [160] –
Selective antagonists BI6015 [67] –
Comments HNF4α has constitutive transactivation activity [160] and binds DNA as a homodimer [59]. –
Searchable database: http://www.guidetopharmacology.org/index.jsp 2A. Hepatocyte nuclear factor-4 receptors S236
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Further reading on 2A. Hepatocyte nuclear factor-4 receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Garattini E et al. (2016) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeu-
tic targets in breast-cancer. Oncotarget 7: 42661-42682 [PMID:26894976]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Lu H. (2016) Crosstalk of HNF4αwith extracellular and intracellular signaling pathways in the regu-
lation of hepatic metabolism of drugs and lipids. Acta Pharm Sin B 6: 393-408 [PMID:27709008]
Walesky C et al. (2015) Role of hepatocyte nuclear factor 4α (HNF4α) in cell proliferation and cancer.
Gene Expr. 16: 101-8 [PMID:25700366]
2B. Retinoid X receptors
Nuclear hormone receptors → 2B. Retinoid X receptors
Overview: Retinoid X receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [43]) are NR2B family members activated by alitretinoin and
the RXR-selective agonists bexarotene and LG100268, sometimes referred to as rexinoids. UVI3003 [103] and HX 531 [35] have been described as a pan-RXR antagonists. These receptors form RXR-RAR
heterodimers and RXR-RXR homodimers [20, 91].
Nomenclature Retinoid X receptor-α Retinoid X receptor-β Retinoid X receptor-γ
Systematic nomenclature NR2B1 NR2B2 NR2B3
HGNC, UniProt RXRA, P19793 RXRB, P28702 RXRG, P48443
Sub/family-selective agonists bexarotene [14, 19, 138] bexarotene [14, 19, 138] bexarotene [14, 19, 138]
Selective agonists CD3254 [46] – –
Further reading on 2B. Retinoid X receptors
Germain P et al. (2006) International Union of Pharmacology. LXIII. Retinoid X receptors. Pharma-
col. Rev. 58: 760-72 [PMID:17132853]
Long MD et al. (2015) Vitamin D receptor and RXR in the post-genomic era. J. Cell. Physiol. 230:
758-66 [PMID:25335912]
Menéndez-Gutiérrez MP et al. (2017) The multi-faceted role of retinoid X receptor in bone remod-
eling. Cell. Mol. Life Sci. 74: 2135-2149 [PMID:28105491]
Searchable database: http://www.guidetopharmacology.org/index.jsp 2B. Retinoid X receptors S237
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2C. Testicular receptors
Nuclear hormone receptors → 2C. Testicular receptors
Overview: Testicular receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an endogenous ligand,
although testicular receptor 4 has been reported to respond to retinoids.
Nomenclature Testicular receptor 2 Testicular receptor 4
Systematic nomenclature NR2C1 NR2C2
HGNC, UniProt NR2C1, P13056 NR2C2, P49116
Endogenous agonists – retinol [166], tretinoin [166]
Comments Forms a heterodimer with TR4; gene disruption appears without effect on testicular development or function [127]. Forms a heterodimer with TR2.
Further reading on 2C. Testicular receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Safe S et al. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug
targets. Mol. Endocrinol. 28: 157-72 [PMID:24295738]
Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim.
Biophys. Acta 1866: 23-36 [PMID:27264242]
2E. Tailless-like receptors
Nuclear hormone receptors → 2E. Tailless-like receptors
Overview: Tailless-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an endogenous ligand.
Nomenclature TLX PNR
Systematic nomenclature NR2E1 NR2E3
HGNC, UniProt NR2E1, Q9Y466 NR2E3, Q9Y5X4
Comments Gene disruption is associated with abnormal brain development [71, 99]. –
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Further reading on 2E. Tailless-like receptors
Benod C et al. (2016) TLX: An elusive receptor. J. Steroid Biochem. Mol. Biol. 157: 41-7
[PMID:26554934]
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
O’Leary JD et al. (2018) Regulation of behaviour by the nuclear receptor TLX. Genes Brain Behav.
17: e12357 [PMID:27790850]
2F. COUP-TF-like receptors
Nuclear hormone receptors → 2F. COUP-TF-like receptors
Overview: COUP-TF-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an endogenous
ligand.
Nomenclature COUP-TF1 COUP-TF2 V-erbA-related gene
Systematic nomenclature NR2F1 NR2F2 NR2F6
HGNC, UniProt NR2F1, P10589 NR2F2, P24468 NR2F6, P10588
Comments Gene disruption is perinatally lethal [115]. Gene disruption is embryonically lethal [112]. Gene disruption impairs CNS development [148].
Further reading on 2F. COUP-TF-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim.
Biophys. Acta 1866: 23-36 [PMID:27264242]
Wu SP et al. (2016) Choose your destiny: Make a cell fate decision with COUP-TFII. J. Steroid Biochem.
Mol. Biol. 157: 7-12 [PMID:26658017]
3B. Estrogen-related receptors
Nuclear hormone receptors → 3B. Estrogen-related receptors
Overview: Estrogen-related receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an endogenous
ligand.
Searchable database: http://www.guidetopharmacology.org/index.jsp 3B. Estrogen-related receptors S239
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Nomenclature Estrogen-related receptor-α Estrogen-related receptor-β Estrogen-related receptor-γ
Systematic nomenclature NR3B1 NR3B2 NR3B3
HGNC, UniProt ESRRA, P11474 ESRRB, O95718 ESRRG, P62508
Comments Activated by some dietary ﬂavonoids [133]; activated by the synthetic
agonist GSK4716 [169] and blocked by XCT790 [153].
May be activated by DY131 [159]. May be activated by DY131 [159].
Further reading on 3B. Estrogen-related receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Divekar SD et al. (2016) Estrogen-related receptor β (ERRβ) - renaissance receptor or receptor renais-
sance? Nucl Recept Signal 14: e002 [PMID:27507929]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Tam IS et al. (2016) There and back again: The journey of the estrogen-related receptors in the
cancer realm. J. Steroid Biochem. Mol. Biol. 157: 13-9 [PMID:26151739]
Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim.
Biophys. Acta 1866: 23-36 [PMID:27264242]
4A. Nerve growth factor IB-like receptors
Nuclear hormone receptors → 4A. Nerve growth factor IB-like receptors
Overview: Nerve growth factor IB-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an
endogenous ligand.
Nomenclature Nerve Growth factor IB Nuclear receptor related 1 Neuron-derived orphan receptor 1
Systematic nomenclature NR4A1 NR4A2 NR4A3
HGNC, UniProt NR4A1, P22736 NR4A2, P43354 NR4A3, Q92570
Comments An endogenous agonist, cytosporone B, has been described [161], although structural
analysis and molecular modelling has not identiﬁed a ligand binding site [3, 38, 147].
– –
Further reading on 4A. Nerve growth factor IB-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Ranhotra HS. (2015) The NR4A orphan nuclear receptors: mediators in metabolism and diseases. J.
Recept. Signal Transduct. Res. 35: 184-8 [PMID:25089663]
Rodríguez-Calvo R et al. (2017) The NR4A subfamily of nuclear receptors: potential new therapeu-
tic targets for the treatment of inﬂammatory diseases. Expert Opin. Ther. Targets 21: 291-304
[PMID:28055275]
Safe S et al. (2016) Nuclear receptor 4A (NR4A) family - orphans no more. J. Steroid Biochem. Mol.
Biol. 157: 48-60 [PMID:25917081]
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5A. Fushi tarazu F1-like receptors
Nuclear hormone receptors → 5A. Fushi tarazu F1-like receptors
Overview: Fushi tarazu F1-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an endogenous
ligand.
Nomenclature Steroidogenic factor 1 Liver receptor homolog-1
Systematic nomenclature NR5A1 NR5A2
HGNC, UniProt NR5A1, Q13285 NR5A2, O00482
Comments Reported to be inhibited by AC45594 [29] and SID7969543 [85]. –
Further reading on 5A. Fushi tarazu F1-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Garattini E et al. (2016) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeu-
tic targets in breast-cancer. Oncotarget 7: 42661-42682 [PMID:26894976]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Zhi X et al. (2016) Structures and regulation of non-X orphan nuclear receptors: A retinoid hypoth-
esis. J. Steroid Biochem. Mol. Biol. 157: 27-40 [PMID:26159912]
Zimmer V et al. (2015) Nuclear receptor variants in liver disease. Dig Dis 33: 415-9 [PMID:26045277]
6A. Germ cell nuclear factor receptors
Nuclear hormone receptors → 6A. Germ cell nuclear factor receptors
Overview: Germ cell nuclear factor receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an
endogenous ligand.
Nomenclature Germ cell nuclear factor
Systematic nomenclature NR6A1
HGNC, UniProt NR6A1, Q15406
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Further reading on 6A. Germ cell nuclear factor receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Garattini E et al. (2016) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeu-
tic targets in breast-cancer. Oncotarget 7: 42661-42682 [PMID:26894976]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Safe S et al. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug
targets. Mol. Endocrinol. 28: 157-72 [PMID:24295738]
Zhi X et al. (2016) Structures and regulation of non-X orphan nuclear receptors: A retinoid hypoth-
esis. J. Steroid Biochem. Mol. Biol. 157: 27-40 [PMID:26159912]
0B. DAX-like receptors
Nuclear hormone receptors → 0B. DAX-like receptors
Overview: Dax-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [5]) have yet to be ofﬁcially paired with an endogenous ligand.
Nomenclature DAX1 SHP
Systematic nomenclature NR0B1 NR0B2
HGNC, UniProt NR0B1, P51843 NR0B2, Q15466
Further reading on 0B. DAX-like receptors
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Garattini E et al. (2016) Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeu-
tic targets in breast-cancer. Oncotarget 7: 42661-42682 [PMID:26894976]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Safe S et al. (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug
targets. Mol. Endocrinol. 28: 157-72 [PMID:24295738]
Wu D et al. (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim.
Biophys. Acta 1866: 23-36 [PMID:27264242]
Steroid hormone receptors
Nuclear hormone receptors → Steroid hormone receptors
Overview: Steroid hormone receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee onNuclearHor-
mone Receptors [27, 82]) are nuclear hormone receptors of the
NR3 class, with endogenous agonists that may be divided into
3-hydroxysteroids (estrone and 17β-estradiol) and 3-ketosteroids
(dihydrotestosterone [DHT], aldosterone, cortisol, corticosterone,
progesterone and testosterone). These receptors exist as dimers
coupled with chaperone molecules (such as hsp90β (HSP90AB1,
P08238) and immunophilin FKBP52:FKBP4, Q02790), which are
shed on binding the steroid hormone. Although rapid signalling
phenomena are observed [79, 114], the principal signalling cas-
cade appears to involve binding of the activated receptors to
nuclear hormone response elements of the genome, with a 15-
nucleotide consensus sequence AGAACAnnnTGTTCT (i.e. an in-
verted palindrome) as homo- or heterodimers. They also affect
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transcription by protein-protein interactions with other transcrip-
tion factors, such as activator protein 1 (AP-1) and nuclear factor
κB (NF-κB). Splice variants of each of these receptors can form
functional or non-functional monomers that can dimerize to form
functional or non-functional receptors. For example, alternative
splicing of PR mRNA produces A and B monomers that combine
to produce functional AA, AB and BB receptors with distinct char-
acteristics [142].
A 7TM receptor responsive to estrogen (GPER1, Q99527, also
known as GPR30, see [113]) has been described. Human
orthologues of 7TM ’membrane progestin receptors’ (PAQR7,
PAQR8 and PAQR5), initially discovered in ﬁsh [167, 168], ap-
pear to localize to intracellular membranes and respond to ’non-
genomic’ progesterone analogues independently of G proteins
[129].
3A. Estrogen receptors
Nuclear hormone receptors → Steroid hormone receptors → 3A. Estrogen receptors
Overview: Estrogen receptor (ER) activity regulates diverse physiological processes via transcriptional modulation of target genes. The selection of target genes and the magnitude of the response, be it
induction or repression, are determined by many factors, including the effect of the hormone ligand and DNA binding on ER structural conformation, and the local cellular regulatory environment. The
cellular environment deﬁnes the speciﬁc complement of DNA enhancer and promoter elements present and the availability of coregulators to form functional transcription complexes. Together, these
determinants control the resulting biological response.
Nomenclature Estrogen receptor-α Estrogen receptor-β
Systematic nomenclature NR3A1 NR3A2
HGNC, UniProt ESR1, P03372 ESR2, Q92731
Endogenous agonists estriol [70], estrone [70] –
Selective agonists propylpyrazoletriol [69, 130], ethinylestradiol [58] WAY200070 [88], diarylpropionitrile [95, 130], prinaberel [26, 88]
Sub/family-selective antagonists bazedoxifene (pIC50 7.6) [98] bazedoxifene (pIC50 7.1) [98]
Selective antagonists clomiphene (pKi 8.9) [2], methyl-piperidino-pyrazole (pKi 8.6) [134] R,R-THC (pKi 8.4) [94, 135], PHTPP (pKi 6.9) [165]
Comments: R,R-THC exhibits partial agonist activity at ERα
[94, 135]. Estrogen receptors may be blocked non-selectively by
tamoxifen and raloxifene and labelled by [3H]17β-estradiol and
[3H]tamoxifen. Many agents thought initially to be antagonists
at estrogen receptors appear to have tissue-speciﬁc efﬁcacy (e.g.
Tamoxifen is an antagonist at estrogen receptors in the breast, but
is an agonist at estrogen receptors in the uterus), hence the de-
scriptor SERM (selective estrogen receptor modulator) or SnuRM
(selective nuclear receptor modulator). Y134 has been suggested
to be an ERα-selective estrogen receptor modulator [106].
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Further reading on 3A. Estrogen receptors
Coons LA et al. (2017) DNA Sequence Constraints Deﬁne Functionally Active Steroid Nuclear Re-
ceptor Binding Sites in Chromatin. Endocrinology 158: 3212-3234 [PMID:28977594]
Dahlman-Wright K et al. (2006) International Union of Pharmacology. LXIV. Estrogen receptors.
Pharmacol. Rev. 58: 773-81 [PMID:17132854]
Gonzalez-Sanchez E et al. (2015) Nuclear receptors in acute and chronic cholestasis. Dig Dis 33:
357-66 [PMID:26045270]
Hewitt SC et al. (2016) What’s new in estrogen receptor action in the female reproductive tract. J.
Mol. Endocrinol. 56: R55-71 [PMID:26826253]
Jameera Begam A et al. (2017) Estrogen receptor agonists/antagonists in breast cancer therapy: A
critical review. Bioorg. Chem. 71: 257-274 [PMID:28274582]
Warner M et al. (2017) Estrogen Receptor β as a Pharmaceutical Target. Trends Pharmacol. Sci. 38:
92-99 [PMID:27979317]
3C. 3-Ketosteroid receptors
Nuclear hormone receptors → Steroid hormone receptors → 3C. 3-Ketosteroid receptors
Overview: Steroid hormone receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [27, 82]) are nuclear hormone receptors of the NR3 class,
with endogenous agonists that may be divided into 3-hydroxysteroids (estrone and 17β-estradiol) and 3-ketosteroids (dihydrotestosterone [DHT], aldosterone, cortisol, corticosterone, progesterone and
testosterone).
Nomenclature Androgen receptor Glucocorticoid receptor Mineralocorticoid receptor Progesterone receptor
Systematic nomenclature NR3C4 NR3C1 NR3C2 NR3C3
HGNC, UniProt AR, P10275 NR3C1, P04150 NR3C2, P08235 PGR, P06401
Rank order of potency dihydrotestosterone > testosterone cortisol, corticosterone  aldosterone,
deoxycortisone [120]
corticosterone, cortisol, aldosterone,
progesterone [120]
progesterone
Endogenous agonists dihydrotestosterone [139] – aldosterone [54, 120] progesterone [36]
Selective agonists testosterone propionate [90], mibolerone
[47], ﬂuoxymesterone [57],
methyltrienolone [145],
dromostanolone propionate
ﬂuticasone propionate [8], ﬂunisolide [2],
beclometasone [2], methylprednisolone
[2], betamethasone [2], budesonide [97]
– medroxyprogesterone (Afﬁnity at human
PR-A) [163], ORG2058, levonorgestrel [7,
123]
Selective antagonists bicalutamide (pKi 7.7) [66], PF0998425
(pIC50 7.1–7.5) [81], enzalutamide
(pIC50 7.4) [140], nilutamide (pIC50
7.1–7.1) [128], hydroxyﬂutamide (pEC50
6.6) [145], galeterone (pIC50 6.4) [53],
ﬂutamide (Displacement of 3[H]
testosterone from wild-type androgen
receptors) (pKi 5.4) [144]
onapristone (pIC50 7.6) [162], ZK112993 ﬁnerenone (pIC50 7.7) [18], eplerenone
(pKi 6.9) [4], onapristone (pIC50 6.3)
[162], RU28318, ZK112993
ulipristal acetate (pIC50 9.7) [118],
mifepristone (Mixed) (pKi 9) [164],
onapristone (pKi 7.7) [52], ZK112993
Labelled ligands [3H]dihydrotestosterone (Selective
Agonist), [3H]methyltrienolone (Selective
Agonist), [3H]mibolerone (Agonist)
[3H]dexamethasone (Agonist) [3H]aldosterone (Selective Agonist) [42,
132] – Rat
[3H]ORG2058 (Selective Agonist)
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Comments: [3H]dexamethasone also binds to MRin vitro. PR antagonists have been suggested to subdivide into Type I (e.g. onapristone) and Type II (e.g. ZK112993) groups. These groups appear to
promote binding of PR to DNA with different efﬁcacies and evoke distinct conformational changes in the receptor, leading to a transcription-neutral complex [41, 78]. Mutations in AR underlie testicular
feminization and androgen insensitivity syndromes, spinal and bulbar muscular atrophy (Kennedy’s disease).
Further reading on 3C. 3-Ketosteroid receptors
Baker ME et al. (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Evolution of the
mineralocorticoid receptor: sequence, structure and function. J. Endocrinol. 234: T1-T16
[PMID:28468932]
Carroll JS et al. (2017) Deciphering the divergent roles of progestogens in breast cancer. Nat. Rev.
Cancer 17: 54-64 [PMID:27885264]
Cohen DM et al. (2017) Nuclear Receptor Function through Genomics: Lessons from the Glucocor-
ticoid Receptor. Trends Endocrinol. Metab. 28: 531-540 [PMID:28495406]
de Kloet ER et al. (2017) Brain mineralocorticoid receptor function in control of salt balance and
stress-adaptation. Physiol. Behav. 178: 13-20 [PMID:28089704]
Garg D et al. (2017) Progesterone-Mediated Non-Classical Signaling. Trends Endocrinol. Metab. 28:
656-668 [PMID:28651856]
Lu NZ et al. (2006) International Union of Pharmacology. LXV. The pharmacology and classiﬁca-
tion of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and
androgen receptors. Pharmacol. Rev. 58: 782-97 [PMID:17132855]
Lucas-Herald AK et al. (2017) Genomic and non-genomic effects of androgens in the cardiovascular
system: clinical implications. Clin. Sci. 131: 1405-1418 [PMID:28645930]
Wadosky KM et al. (2017) Androgen receptor splice variants and prostate cancer: From bench to
bedside. Oncotarget 8: 18550-18576 [PMID:28077788]
Weikum ER et al. (2017) Glucocorticoid receptor control of transcription: precision and plasticity
via allostery. Nat. Rev. Mol. Cell Biol. 18: 159-174 [PMID:28053348]
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